Grassi G, Cattaneo B M, Seravalle G, Lanfranchi A, Pozzi M, Morganti A, Carugo S, Mancia G
Cattedra di Medicina Interna, Università di Milano, Italy.
Circulation. 1997 Aug 19;96(4):1173-9. doi: 10.1161/01.cir.96.4.1173.
In congestive heart failure ACE inhibitors chronically reduce plasma norepinephrine. No information exists, however, on whether and to what extent this reduction reflects a true chronic inhibition of sympathetic outflow and which mechanisms may be responsible.
In 24 patients aged 60.3+/-2.0 years (mean+/-SEM) affected by congestive heart failure (New York Heart Association class II) and treated with diuretics and digitalis, we measured mean arterial pressure (Finapres), plasma renin activity and angiotensin II levels (radioimmunoassay), plasma norepinephrine (high-performance liquid chromatography), and muscle sympathetic nerve activity (microneurography at a peroneal nerve) at rest and during baroreceptor stimulation and deactivation caused by stepwise intravenous infusions of phenylephrine and nitroprusside, respectively. In 12 patients measurements were repeated after a 2-month addition of the ACE inhibitor benazepril (10 mg/d P.O.), while in the remaining 12 patients they were performed again after 2 months without any treatment modifications. Benazepril did not alter mean arterial pressure, markedly increased plasma renin activity, reduced plasma angiotensin II, and caused a nonsignificant reduction in plasma norepinephrine. In contrast, muscle sympathetic nerve traffic was significantly reduced (-30.5+/-5.3%, P<.01). This reduction was accompanied by no change in the sympathoexcitatory responses to baroreceptor deactivation but by a marked enhancement of the sympathoinhibitory responses to baroreceptor stimulation (103.5+/-3.4%).
These results provide the first direct evidence that in congestive heart failure chronic ACE inhibitor treatment is accompanied by a marked reduction in central sympathetic outflow. This reduction may depend on a persistent restoration of baroreflex restraint on the sympathetic neural drive.
在充血性心力衰竭患者中,血管紧张素转换酶(ACE)抑制剂可长期降低血浆去甲肾上腺素水平。然而,目前尚无关于这种降低是否以及在何种程度上反映了对交感神经输出的真正慢性抑制,以及哪些机制可能起作用的信息。
我们对24例年龄为60.3±2.0岁(均值±标准误)的充血性心力衰竭患者(纽约心脏协会II级)进行了研究,这些患者接受利尿剂和洋地黄治疗。我们测量了静息状态下以及在分别通过静脉输注去氧肾上腺素和硝普钠进行压力感受器刺激和失活过程中的平均动脉压(Finapres)、血浆肾素活性和血管紧张素II水平(放射免疫测定)、血浆去甲肾上腺素(高效液相色谱法)以及肌肉交感神经活动(通过腓总神经进行微神经ography)。12例患者在加用ACE抑制剂苯那普利(10mg/d口服)2个月后重复测量,而其余12例患者在未进行任何治疗调整的情况下2个月后再次测量。苯那普利未改变平均动脉压,显著增加血浆肾素活性,降低血浆血管紧张素II,并使血浆去甲肾上腺素出现不显著的降低。相比之下,肌肉交感神经活动显著降低(-30.5±5.3%,P<0.01)。这种降低伴随着对压力感受器失活的交感兴奋反应无变化,但对压力感受器刺激的交感抑制反应显著增强(103.5±3.4%)。
这些结果提供了首个直接证据,表明在充血性心力衰竭患者中,慢性ACE抑制剂治疗伴随着中枢交感神经输出的显著降低。这种降低可能取决于压力反射对交感神经驱动的持续恢复抑制作用。